All News

Found 834 articles

• Cara Therapeutics to Present at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.

• Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

  5/18/2023

  Vifor Fresenius Medical Care Renal Pharma today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia ® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

• Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

  5/18/2023

  Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England's National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

• Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting

  5/16/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

• Cara Therapeutics Reports First Quarter 2023 Financial Results

  5/15/2023

  Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2023.

• Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights

  5/11/2023

  Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments.

• Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

  5/3/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH).

• Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

  5/1/2023

  Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

• Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

  4/10/2023

  Cara Therapeutics, Inc. today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

• SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full Year 2022

  4/3/2023

  SWK Holdings Corporation, a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2022.

• Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting

  3/15/2023

  Homology Medicines, Inc. announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria and the Phase 1 juMPStart gene therapy trial for Hunter syndrome.

• Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

  3/14/2023

  Cara Therapeutics, Inc. released its inaugural Environmental, Social, and Governance report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.

• Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer

  3/9/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer.

• Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

  3/9/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments.

• Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

  3/6/2023

  Cara Therapeutics, Inc. today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2022.

• Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

  3/2/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.

• Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting

  2/22/2023

  Homology Medicines, Inc. announced the presentation of preclinical data that supports the targeted, prophylactic immunosuppression regimen in the ongoing pheEDIT gene editing clinical trial in adults with phenylketonuria and juMPStart gene therapy trial in adults with Hunter syndrome.

• Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

  2/21/2023

  Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.

• Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

  2/16/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023.

• Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

  2/8/2023

  Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the New England Journal of Medicine (NEJM) has published results from the KOMFORT Phase 2 clinical trial of oral difelikefalin in patients with moderate-to-severe pruritus from notalgia paresthetica.